Cargando…
848. Approaches to Optimize Recruitment of Historically Underrepresented Black and Hispanic/LatinX MSM, Transgender, and Gender Non-binary Individuals into the Lenacapavir for PrEP (PURPOSE 2) Trial
BACKGROUND: Black and Hispanic/Latinx gay and other men who have sex with men (MSM), transgender women (TGW), transgender men (TGM), and gender nonbinary individuals (GNB) have been historically underrepresented in HIV prevention trials despite being disproportionately affected by the disease. There...
Autores principales: | Cespedes, Michelle, Blumenthal, Jill, Mounzer, Karam, Ramgopal, Moti, Hodge, Theo, Elliott, Ayana, Demidont, A C, Chauncey Watson, C, Carter, Christoph C, Kintu, Alex, Das, Moupali, Baeten, Jared, Ogbuagu, Onyema |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643746/ http://dx.doi.org/10.1093/ofid/ofab466.1043 |
Ejemplares similares
-
Proactive strategies to optimize engagement of Black, Hispanic/Latinx, transgender, and nonbinary individuals in a trial of a novel agent for HIV pre-exposure prophylaxis (PrEP)
por: Cespedes, Michelle, et al.
Publicado: (2022) -
1596. Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV: Week 104 Results
por: Ogbuagu, Onyema, et al.
Publicado: (2023) -
1585. Efficacy and safety of long-acting subcutaneous lenacapavir in heavily treatment-experienced people with multi-drug resistant HIV: Week 52 results
por: Ogbuagu, Onyema, et al.
Publicado: (2022) -
Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2022) -
Correction to: Lenacapavir: First Approval
por: Paik, Julia
Publicado: (2023)